The U.S. breast biopsy devices market size was estimated at USD 1.95 billion in 2025 and is predicted to increase from USD 2.1 billion in 2026 to approximately USD 4.13 billion by 2035, expanding at a CAGR of 7.8% from 2026 to 2035. The market is expanding as early detection programs and routine mammography are increasing the number of biopsy procedures performed each year. In addition, advances in precision-guided and minimally invasive devices are improving diagnostic confidence, which is accelerating adoption across healthcare facilities.
U.S. breast biopsy devices are advanced diagnostic instruments designed to collect breast tissue samples with high precision, supporting early detection of cancer and other abnormalities through minimally invasive and image-guided procedures. The U.S. breast biopsy devices market is growing due to the increasing burden of breast cancer and the strong focus in early diagnosis. Higher screening rates, wider use of mammography, and demand for minimally invasive procedure are driving procedures volume. In addition, advancements in vacuum-assisted, ultrasound-guided, and AI-supported biopsy systems are improving accuracy and patient comfort, accelerating adoption across hospitals, imaging centers, and speciality clinics.
The U.S. breast biopsy devices market is expanding to see strong opportunities through AI-based imaging support, advanced minimally invasive devices, and increasing expansion of outpatient diagnostic centers. Growing demand for faster and more precise diagnostic centers. Growing demand for faster and more precise tissue diagnosis is also creating room for innovation in portable and MRI-compatible systems.
| Year | 2024 | 2025 |
| Cases | 310,720 | 316,950 |
| Deaths | 42,250 | 42,170 |
The comparative rise in U.S. breast cancer cases and related deaths highlights the growing clinical burden and the need for timely diagnosis. Increasing incidence directly drives demand for breast biopsy procedures to confirm malignancy at an early stage. At the same time, mortality trends emphasize the importance of accurate and minimally invasive diagnostic technologies, supporting the continued growth of the U.S. breast biopsy devices market.
The needle-based biopsy instruments segment dominated the market with a share of 58% in 2025 due to its high accuracy, minimally invasive approach, and cost-effectiveness. These devices enable precise tissue sampling with less discomfort and faster recovery compared to surgical methods. Their widespread use in hospitals, imaging centers, and outpatient settings has significantly strengthened their leading market position.
The vacuum-assisted biopsy segment led the market with shares of 34% in 2025 because it allows larger and more accurate tissue sample collection with fewer insertions. This reduces patient discomfort, improves diagnostic confidence, and shortens procedure time. Its strong use in image-guided breast cancer diagnosis across hospitals and imaging centers has driven its market leadership.
The ultrasound-guided biopsy segment dominated the U.S. breast biopsy devices market with 42% market share in 2025 due to its real imaging capabilities, accuracy, and cost efficiency. It helps clinicians precisely target suspicious lesions with minimal invasiveness, reducing procedure time and patient discomfort. Its widespread availability and routine use in breast diagnostics continue to support strong market demand.
The hospital segment held the largest market share of 52% due to advanced imaging infrastructure, availability of skilled radiologists, and high patient inflow for breast cancer diagnosis. Hospitals perform a large volume of image-guided and minimally invasive biopsy procedures, making them the primary end-user and a key contributor to overall revenue growth.
The breast cancer diagnostic segment held the largest market share of 88% in 2025 because biopsy procedures are primarily performed to confirm suspicious breast lesions detected during screening. Rising breast cancer incidence, increased mammography use, and the need for early, accurate diagnosis continue to drive strong demand, making this the most significant application area in the market.
The Northeast and West Coast regions lead the U.S. breast biopsy devices market due to strong healthcare infrastructure, higher screening awareness, and greater adoption of advanced imaging technologies. According to SEER, the U.S. is expected to report 316,950 new cancers in 2025, creating strong demand nationwide. States like California, New York, and Massachusetts show high procedure volume due to advanced hospital networks and specialty breast care centers.
The U.S. breast biopsy devices market is highly competitive, with Hologic, Mammotome, BD, Merit Medical, and GE HealthCare holding strong positions through advanced biopsy and imaging-guided solutions. In addition, companies such as Argon Medical, Cook Medical, Siemens Healthineers, and Fujifilm Healthcare are expanding their market presence, while newer innovators are gaining momentum through specialized localization and minimally invasive diagnostic technologies.
By Product
By Technology
By Guidance Technique
By End User
By Application
